Aspire Biopharma Holdings, Inc.ASBPEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
ASBP Q3 FY2025 Key Financial Metrics
Revenue
$1.9K
Gross Profit
$884
Operating Profit
$-1.1M
Net Profit
$-1.9M
Gross Margin
45.5%
Operating Margin
-59015.8%
Net Margin
-95337.1%
YoY Growth
N/A
EPS
$-0.04
Aspire Biopharma Holdings, Inc. Q3 FY2025 Financial Summary
Aspire Biopharma Holdings, Inc. reported revenue of $1.9K for Q3 FY2025, with a net profit of $-1.9M (down 755.6% YoY) (-95337.1% margin). Cost of goods sold was $1.1K, operating expenses totaled $1.1M.
Key Financial Metrics
| Total Revenue | $1.9K |
|---|---|
| Net Profit | $-1.9M |
| Gross Margin | 45.5% |
| Operating Margin | -59015.8% |
| Report Period | Q3 FY2025 |
Income Statement
| Q3 2025 | |
|---|---|
| Revenue | $1941 |
| YoY Growth | N/A |
Balance Sheet
| Q3 2025 | |
|---|---|
| Assets | $2.4M |
| Liabilities | $13.9M |
| Equity | $-11.5M |
Cash Flow
| Q3 2025 | |
|---|---|
| Operating CF | $-1.1M |